Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2025 Jan 8

PMID 39769907

Authors

Maria Saveria Gilardini Montani

Rossella Benedetti

Mara Cirone

Affiliations

Soon will be listed here.

Abstract

Enhancer of zeste homolog 2 (EZH2) is a methyltransferase involved in cell cycle regulation, cell differentiation, and cell death and plays a role in modulating the immune response. Although it mainly functions by catalyzing the tri-methylation of H3 histone on K27 (H3K27), to inhibit the transcription of target genes, EZH2 can directly methylate several transcription factors or form complexes with them, regulating their functions. EZH2 expression/activity is often dysregulated in cancer, contributing to carcinogenesis and immune escape, thereby representing an important target in anti-cancer therapy. This review summarizes some of the mechanisms through which EZH2 regulates the expression and function of tumor suppressor genes and oncogenic molecules such as STAT3, mutant p53, and c-Myc and how it modulates the anti-cancer immune response. The influence of posttranslational modifications on EZH2 activity and stability and the possible strategies leading to its inhibition are also reviewed.

References

Sanulli S, Justin N, Teissandier A, Ancelin K, Portoso M, Caron M . Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation. Mol Cell. 2015; 57(5):769-783. PMC: 4352895. DOI: 10.1016/j.molcel.2014.12.020. View

Varambally S, Dhanasekaran S, Zhou M, Barrette T, Kumar-Sinha C, Sanda M . The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-9. DOI: 10.1038/nature01075. View

He A, Shen X, Ma Q, Cao J, von Gise A, Zhou P . PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev. 2012; 26(1):37-42. PMC: 3258964. DOI: 10.1101/gad.173930.111. View

Ko H, Lee H, Huo L, Xia W, Yang C, Hsu J . GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016; 7(35):57131-57144. PMC: 5302978. DOI: 10.18632/oncotarget.11008. View

Xia L, Zhu X, Zhang L, Xu Y, Chen G, Luo J . EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer. Biotechnol Appl Biochem. 2019; 67(6):1011-1019. PMC: 7818479. DOI: 10.1002/bab.1875. View

Cha T, Zhou B, Xia W, Wu Y, Yang C, Chen C . Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005; 310(5746):306-10. DOI: 10.1126/science.1118947. View

Chu C, Lo P, Yeh Y, Hsu P, Peng S, Teng Y . O-GlcNAcylation regulates EZH2 protein stability and function. Proc Natl Acad Sci U S A. 2014; 111(4):1355-60. PMC: 3910655. DOI: 10.1073/pnas.1323226111. View

Wang X, Cao W, Zhang J, Yan M, Xu Q, Wu X . A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. EMBO J. 2017; 36(9):1243-1260. PMC: 5412902. DOI: 10.15252/embj.201694058. View

Lee J, Lee J, Kim H, Kim K, Park H, Kim J . EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell. 2012; 48(4):572-86. DOI: 10.1016/j.molcel.2012.09.004. View

10.

Kim J, Lee Y, Lu X, Song B, Fong K, Cao Q . Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Rep. 2018; 25(10):2808-2820.e4. PMC: 6342284. DOI: 10.1016/j.celrep.2018.11.035. View

11.

Fujii S, Ito K, Ito Y, Ochiai A . Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem. 2008; 283(25):17324-32. PMC: 2427338. DOI: 10.1074/jbc.M800224200. View

12.

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

13.

Pang B, Zheng X, Tian J, Gao T, Gu G, Zhang R . EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1α signaling. Oncotarget. 2016; 7(29):45134-45143. PMC: 5216711. DOI: 10.18632/oncotarget.9761. View

14.

Wang X, Long Y, Paucek R, Gooding A, Lee T, Burdorf R . Regulation of histone methylation by automethylation of PRC2. Genes Dev. 2019; 33(19-20):1416-1427. PMC: 6771386. DOI: 10.1101/gad.328849.119. View

15.

Li Z, Wang D, Lu J, Huang B, Wang Y, Dong M . Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell Death Differ. 2020; 27(12):3226-3242. PMC: 7853151. DOI: 10.1038/s41418-020-00615-9. View

16.

Dou F, Tian Z, Yang X, Li J, Wang R, Gao J . Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. Drug Discov Ther. 2022; 16(6):297-299. DOI: 10.5582/ddt.2022.01085. View

17.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

18.

Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, Colleaux L . The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet. 2000; 8(3):174-80. DOI: 10.1038/sj.ejhg.5200439. View

19.

Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P . Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298(5595):1039-43. DOI: 10.1126/science.1076997. View

20.

Lee S, Oh Y, Lu Y, Kim W, Yoo A . MicroRNAs Overcome Cell Fate Barrier by Reducing EZH2-Controlled REST Stability during Neuronal Conversion of Human Adult Fibroblasts. Dev Cell. 2018; 46(1):73-84.e7. PMC: 6082428. DOI: 10.1016/j.devcel.2018.06.007. View